UK markets close in 6 hours 46 minutes

The fight against COVID19

The fight against COVID19

23.81k followers14 symbols Watchlist by TREA

Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.

Curated by TREA

TREA analyses over 100 million data points, interactions, relationships on company research and development activities, allowing investors to quickly gain insight without having to go through complex regulatory filings. Primary data sources include: US FDA (US Food and Drug Administration), US NIH (US National Institutes of Health), USPTO (US Patent and Trademark Office). The search parameters for generating this watchlist were (1) Above sector average Innovation Index score, (2) IP history of at least 5 years (3) COVID19 (4) 2019-nCov (5) SARS-CoV-2, among others.


WatchlistChange today1-month return1-year returnTotal return
The fight against COVID19-0.03%---

14 symbols

SymbolCompany nameLast priceChange% changeMarket timeVolumeAvg vol (3-month)Market cap
JNJJohnson & Johnson157.86+1.31+0.84%16:00 GMT-59.13M7.17M380.25B
ABBVAbbVie Inc.175.75-1.74-0.98%16:00 GMT-55.47M5.42M310.29B
PFEPfizer Inc.27.59-0.03-0.11%16:01 GMT-534.10M47.02M155.78B
SNYSanofi46.85+0.67+1.45%16:00 GMT-52.27M1.74M117.25B
REGNRegeneron Pharmaceuticals, Inc.946.87-1.18-0.12%16:00 GMT-5417.73k570.59k103.93B
GILDGilead Sciences, Inc.72.04+0.46+0.64%16:00 GMT-57.64M7.30M89.76B
GSKGlaxoSmithKline plc42.02+0.08+0.19%16:00 GMT-53.95M3.43M85.42B
TAKTakeda Pharmaceutical Company Limited14.82+0.20+1.37%16:00 GMT-51.84M1.87M46.68B
MRNAModerna, Inc.86.99-1.38-1.56%16:00 GMT-53.09M4.81M33.17B
BNTXBioNTech SE91.24-0.43-0.47%16:00 GMT-5390.36k723.87k21.69B
VIRVir Biotechnology, Inc.10.23-0.02-0.20%16:00 GMT-5894.80k1.11M1.38B
NVAXNovavax, Inc.4.13-0.03-0.72%16:00 GMT-53.25M7.71M490.60M
INOInovio Pharmaceuticals, Inc.8.17+0.24+3.03%16:00 GMT-5556.46k391.66k185.86M
  • Reuters

    GSK's injectable HIV drug shows promise over daily pills

    British drugmaker GSK said on Wednesday its long-acting injectable HIV therapy showed promise in keeping the viral load suppressed compared to daily oral treatment, especially in individuals facing challenges with pill intake. The interim analysis of a late-stage trial on the therapy known as Cabenuva demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of adherence challenges to oral antiretroviral treatment, which is used to suppress and mitigate the progression of the disease. The lack of consistent adherence is a common reason why some people living with HIV struggle to keep the virus in check, GSK said.

  • Yahoo Finance UK

    Falling interest rates give Jeremy Hunt £23bn headroom to cut taxes

    Resolution Foundation warns that tax cuts will be 'sandwiched' between bigger past and future tax rises.


    Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight

    Unraveling the Financials and Future Prospects of AbbVie Inc